Related Experiment Video

Updated: Jul 14, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Targeting TRIP13 for overcoming anticancer drug resistance (Review)

Liwen Zhao1, Siyu Ye1, Shengnan Jing1

  • 1Institute of Pain Medicine and Special Environmental Medicine, Co‑innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu 226019, P.R. China.

Oncology Reports
|October 6, 2023
PubMed

Insights

Thyroid hormone receptor interactor 13 (TRIP13) drives cancer drug resistance by disrupting cell division and repair. Inhibiting TRIP13 offers a promising strategy to overcome treatment resistance in cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer remains a major threat to human health, with drug resistance significantly hindering effective treatment.
  • Thyroid hormone receptor interactor 13 (TRIP13), an AAA+ ATPase, is implicated in promoting cancer treatment resistance.
  • The precise molecular mechanisms of TRIP13-mediated anticancer drug resistance are not fully understood.

Purpose of the Study:

  • To investigate the role of TRIP13 expression in anticancer drug resistance.
  • To explore potential therapeutic strategies to overcome TRIP13-driven resistance.
  • To elucidate the molecular mechanisms by which TRIP13 confers resistance to anticancer drugs.

Main Methods:

  • Literature review and analysis of existing studies on TRIP13 function in cancer.
  • Exploration of TRIP13's involvement in mitotic checkpoint malfunction, DNA repair, autophagy, and immune evasion.
  • Discussion of combination therapies involving TRIP13 inhibitors.

Main Results:

  • TRIP13 expression is a key factor in the development of resistance to anticancer medications.
  • TRIP13 promotes resistance through mechanisms including mitotic checkpoint malfunction, enhanced DNA repair, increased autophagy, and evasion of immune clearance.
  • Combination treatments targeting TRIP13 alongside other inhibitors show potential for overcoming resistance.

Conclusions:

  • TRIP13 is a critical mediator of anticancer drug resistance.
  • Targeting TRIP13 presents a viable therapeutic strategy to improve cancer treatment outcomes.
  • Further research into TRIP13 inhibitors and combination therapies is warranted to enhance current anticancer options.
Keywords:
anticancer drug resistancecombination therapythyroid hormone receptor interactor 13

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K